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Recent advances in G-protein-coupled receptor structural biology have provided only limited
insight into the active conformations of these key signaling molecules. A paper from Nygaard
et al. reveals the dynamic nature of GPCRs along the activation pathway by complementing
NMR experiments with ultralong-timescale molecular dynamics simulations.G-protein-coupled receptors (GPCRs)—
numbering perhaps 900 in the human
genome—represent the largest class of
receptors in the human genome as well
as the single largest class of targets for
therapeutic drug discovery (Allen and
Roth, 2011). We are currently in the midst
of a ‘‘golden era of GPCR structural
biology,’’ with nearly 20 high-resolution
GPCR structures having appeared since
2007 (Stevens et al., 2012) and several
more likely to appear in coming months.
These structures add immensely to
our understanding of ligand binding to
GPCRs; however, the majority represent
inactive antagonist-bound conforma-
tions, and as a consequence, our under-
standing of the precise details respon-
sible for agonist- and G-protein-initiated
conformational changes is lacking. In
this issue of Cell, the Kobilka and Shaw
groups bring NMR and computational
modeling to bear on the question of
how b2-adrenergic receptors achieve
their active conformation (Nygaard et al.,
2013).
Despite the recent wealth of GPCR
X-ray structures, we currently have only
one structure of the elusive ‘‘ternary
complex’’ (De Lean et al., 1980) contain-
ing receptor, agonist, and G protein
(Rasmussen et al., 2011). Although crystal
structures will provide invaluable informa-
tion regarding the active state, they only
represent a snapshot of the likely confor-
mational states induced by agonist and
G protein binding. Ultimately, it will take
many distinct ‘‘frozen’’ receptor confor-
mations to fully appreciate the conforma-
tional dynamics associated with GPCR
activation. In the past 2 years, spectacularprogress has been made on two fronts:
NMR-based studies elucidating ligand-
induced receptor dynamics (Liu et al.,
2012) and long-timescale molecular
dynamics simulations (Dror et al., 2011).
Bringing these two approaches together,
a team led by Brian Kobilka combined
heteronuclear single-quantum coher-
ence (HSQC) spectroscopy using C13
methionine with long-range molecular
dynamics simulation to provide provoca-
tive new insights into the conformational
dynamics associated with G protein and
agonist binding to b2-adrenergic recep-
tors (b2ARs).
Because visualizing every residue by
NMR to fully elucidate GPCR dynamics
is beyond the scope of current technolo-
gies, Nygaard et al. instead sampled the
chemical environment of five strategically
located methionine residues in the bAR.
They examined residues in regions of the
receptor that are known to undergo
dynamic changes and were able to iden-
tify distinct conformational states that
are, perhaps, indicative of various GPCR
states. The timescale in which apparent
receptor motions occur has a critical role
in determining the shape of the NMR
peaks, and it was intriguing that the time-
scales and positions appeared to nicely
complement the long-time molecular
dynamics simulations performed inde-
pendently. The molecular dynamics simu-
lations require a special-purpose com-
puter (a.k.a., ‘‘Anton’’) (Shaw et al., 2008)
designed to accelerate classical MD
simulations by orders of magnitude,
allowing the authors to simulate confor-
mational changes on much longer time-
scales than previously possible.Cell 152The proposed model resulting from this
collaborative work suggests that both the
cytoplasmic and extracellular halves of
the receptor are highly dynamic (Figure 1).
Upon agonist binding, the extracellular
half is stabilized into an active-like confor-
mation while the cytoplasmic half appar-
ently becomes more mobile. Presumably,
by thus exploring many structural con-
formations, the receptor has the potential
to interact with multiple partners. Indi-
vidual cofactors may then bind to and
stabilize a different conformation. It is
now clear that some ligands are ‘‘biased’’
in that they preferentially induce signaling
through one pathway (e.g., G-protein-
mediated signaling) versus another (e.g.,
arrestin-mediated signaling), although
the molecular mechanisms responsible
for these differences are unknown (Urban
et al., 2007). The authors suggest that
such biased ligands trigger distinct
changes in the cytoplasmic half of the
receptor, leading to a receptor with dras-
tically limited dynamic properties. Biased
ligands appear then to facilitate the inter-
action with certain signaling partners with
higher probability (see Figure 1). The
model proposed, based on these results
and those of others (Liu et al., 2012), is
that biased ligands that preferentially
stabilize noncanonical arrestin-ergic sig-
naling have an overall lower effect on
receptor conformations than unbiased
ligands.
Theproposedmodel does not yet clarify
how interactions with different cellular
partners (e.g., G proteins, arrestins and
so on) affect the observed dynamic struc-
tural ensemble. Certainly, GPCRs can
interact with G proteins independently of, January 31, 2013 ª2013 Elsevier Inc. 385
Figure 1. GPCR Conformational Ensembles Illuminated
(1) The ligand-free receptor samples a large spectrum of available confor-
mations ranging from active (red) to inactive (blue). (2) Inverse agonists
stabilize the inactive ensembles of conformations (blue). (3) Extracellular
agonist binding promotes an enrichment of ‘‘signaling’’ ensembles (gray) at the
cytoplasmic end of the receptor. Nygaard et al. suggest that ‘‘biased’’ agonists
can both promote and inhibit conformational ensembles, thus promoting the
interactions of the receptor with different cellular partners. (4) The signaling
ensemble favored by the agonist is further stabilized by the interaction with the
G protein mimetic NB80. As a consequence, binding of both agonist and G
protein analog are necessary for achieving the fully active conformation. (5) We
also illustrate a proposed effect that interaction of a GPCR with a G protein
could have on the agonist binding properties of the receptor; presumably, this
G protein complex would shift the structural space of the extracellular half of
the receptor toward states that favor agonist binding.agonist and thereby allosteri-
cally modulate GPCR struc-
ture (Yan et al., 2008). Based
on the results presented
here, one can speculate that
the interactions with G pro-
teins shift the conformational
ensembles of the extracellular
half of the receptor to those
favoring agonists. Further
study is needed to determine
the differences between the
dynamic ensembles cor-
related with different biased
ligands and to clarify how
different cellular partners
change GPCR dynamics. Ad-
ditionally, comparing high-
resolution structures (e.g.,
via X-ray crystallography) of
arrestin-biased versus full
agonists will help to explicate
how different ligands can in-
duce drastically different pat-
terns of intracellular signaling.
Because it is well accepted
that GPCRs—like all pro-
teins—continuously vibrate,
their dynamic nature allowsthem to execute the myriad roles they
have in biology (Kenakin, 2002).Modifying
the dynamic range of a GPCR and the
conformational space that it can subse-
quently explore results in changes in its
activity—in this case, the activation of
a specific signaling pathway. Illuminating
the dynamic nature of GPCRs, as done
here, offers a key to understanding the
molecular mechanisms of biased and386 Cell 152, January 31, 2013 ª2013 Elsevienonbiased signaling. As shown here
(Nygaard et al., 2013), the ability to follow
the chemical environments of strategi-
cally placed methionines within a proto-
typical GPCR combined with incredibly
long molecular dynamics simulations
now places the dynamic behavior of the
receptor into a structural context and
provides initial glimpses of the protein
dynamics that lead to signaling.r Inc.REFERENCES
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